세계의 환자 유래 이종 이식편(PDX) 모델 시장 : 산업 규모, 동향, 기회, 예측 - 종양 유형별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)

The Global Patient-Derived Xenograft (PDX) Model Market was valued at USD 2.26 billion in 2024 and is projected to reach USD 4.00 billion by 2030, growing at a CAGR of 9.98% during the forecast period. This growth is being driven by the model's expanding role in cancer research and personalized medicine. PDX models, created by implanting human tumor tissue into immunodeficient mice, offer a clinically relevant platform that closely mirrors human tumor behavior, making them invaluable in studying cancer progression and evaluating new therapies. As global cancer incidence rises, the need for accurate and predictive preclinical models becomes increasingly critical. PDX models preserve the genetic and molecular characteristics of original tumors, offering researchers a more precise tool for evaluating drug efficacy and developing targeted treatments. The shift towards personalized oncology, which tailors therapies to the individual genetic profiles of patients, is further boosting demand for PDX models. These models enable scientists and clinicians to test therapies on patient-derived tumors, predicting treatment responses and advancing more effective and individualized care strategies.

Key Market Drivers

Rising Cancer Incidence and Unmet Medical Needs

The increasing global burden of cancer is a key factor fueling the growth of the PDX model market. With cancer expected to see a 70% increase in new cases over the next two decades, the urgency for innovative treatment options has intensified. PDX models replicate the complexity and heterogeneity of human tumors, making them ideal for understanding tumor biology and testing therapeutic agents. These models maintain critical aspects of patient tumors-such as genetic diversity, microenvironment interactions, and treatment resistance-allowing researchers to evaluate treatment outcomes with greater accuracy. As cancer research shifts towards precision-based therapies, the utility of PDX models in identifying and validating new drug candidates has become even more pronounced. Their ability to model real-world tumor behavior supports drug development pipelines and helps address significant unmet medical needs.

Key Market Challenges

Heterogeneity and Variability

Despite their advantages, PDX models face limitations due to the inherent heterogeneity of human tumors. Tumor samples differ significantly between patients, even within the same cancer type, complicating efforts to create universally representative models. This variability can influence drug response outcomes, affecting the reliability of data and complicating clinical translation. While PDX models retain many biological features of the original tumors, they cannot capture the full extent of molecular and cellular complexity. Furthermore, the engraftment process itself may alter tumor characteristics over time. These limitations highlight the need for ongoing refinement in PDX model development to ensure broader applicability and predictive accuracy in therapeutic evaluation.

Key Market Trends

Rising Interest in Personalized Medicine

The growing adoption of personalized medicine is a major trend shaping the PDX model market. Personalized treatment strategies require models that can mimic patient-specific tumor biology. PDX models allow for the creation of "avatar mice"-animal models implanted with tumor samples from individual patients-which are used to test a range of therapeutic options. These models help clinicians determine the most effective course of treatment, reducing adverse effects and improving outcomes. The integration of PDX models into clinical research has accelerated drug development and enhanced the success rate of oncology trials by providing patient-relevant data. As the pharmaceutical industry increasingly embraces targeted therapies, PDX models are expected to play a crucial role in refining therapeutic selection and reducing trial-and-error approaches in cancer treatment.

Key Market Players

• Charles River Laboratories Inc.
• The Jackson Laboratory
• Crown Bioscience, Inc.
• Altogen Labs
• Envigo
• WuxiAppTec
• Oncodesign
• Hera BioLabs
• XenTech
• Abnova Corporation

Report Scope:

In this report, the Global Patient-Derived Xenograft Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Patient-Derived Xenograft Model Market, By Tumor Type:

• Lung Cancer
• Pancreatic Cancer
• Prostate Cancer
• Breast Cancer
• Other Cancer

Patient-Derived Xenograft Model Market, By End User:

• Inpatient Settings
• Community Settings

Patient-Derived Xenograft Model Market, By Type:

• Rats
• Mice

Patient-Derived Xenograft Model Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Patient-Derived Xenograft Model Market.

Available Customizations:

Global Patient-Derived Xenograft Model Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Patient-Derived Xenograft Model Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer)
  • 5.2.2. By Type (Mice, Rats)
  • 5.2.3. By End-User (Inpatient Settings, Community Settings)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Patient-Derived Xenograft Model Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Tumor Type
  • 6.2.2. By Type
  • 6.2.3. By End-user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Patient-Derived Xenograft Model Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Tumor Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End-user
  • 6.3.2. Mexico Patient-Derived Xenograft Model Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Tumor Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End-user
  • 6.3.3. Canada Patient-Derived Xenograft Model Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Tumor Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End-user

7. Europe Patient-Derived Xenograft Model Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Tumor Type
  • 7.2.2. By Type
  • 7.2.3. By End-user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Patient-Derived Xenograft Model Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Tumor Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End-user
  • 7.3.2. Germany Patient-Derived Xenograft Model Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Tumor Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End-user
  • 7.3.3. United Kingdom Patient-Derived Xenograft Model Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Tumor Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End-user
  • 7.3.4. Italy Patient-Derived Xenograft Model Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Tumor Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End-user
  • 7.3.5. Spain Patient-Derived Xenograft Model Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Tumor Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End-user

8. Asia-Pacific Patient-Derived Xenograft Model Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Tumor Type
  • 8.2.2. By Type
  • 8.2.3. By End-user
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Patient-Derived Xenograft Model Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Tumor Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End-user
  • 8.3.2. India Patient-Derived Xenograft Model Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Tumor Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End-user
  • 8.3.3. South Korea Patient-Derived Xenograft Model Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Tumor Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End-user
  • 8.3.4. Japan Patient-Derived Xenograft Model Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Tumor Type
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End-user
  • 8.3.5. Australia Patient-Derived Xenograft Model Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Tumor Type
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End-user

9. South America Patient-Derived Xenograft Model Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Tumor Type
  • 9.2.2. By Type
  • 9.2.3. By End-user
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Patient-Derived Xenograft Model Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Tumor Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End-user
  • 9.3.2. Argentina Patient-Derived Xenograft Model Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Tumor Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End-user
  • 9.3.3. Colombia Patient-Derived Xenograft Model Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Tumor Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End-user

10. Middle East and Africa Patient-Derived Xenograft Model Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Tumor Type
  • 10.2.2. By Type
  • 10.2.3. By End-user
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Patient-Derived Xenograft Model Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Tumor Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End-user
  • 10.3.2. Saudi Arabia Patient-Derived Xenograft Model Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Tumor Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End-user
  • 10.3.3. UAE Patient-Derived Xenograft Model Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Tumor Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End-user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Charles River Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. The Jackson Laboratory
• 15.3. Crown Bioscience,Inc.
• 15.4. Altogen Labs
• 15.5. Envigo
• 15.6. WuxiAppTec
• 15.7. Oncodesign
• 15.8. Hera BioLabs
• 15.9. XenTech
• 15.10. Abnova Corporation

16. Strategic Recommendation

17. About Us & Disclaimer